Grade ≥3 drug-related AE rates were 59% vs 51%. Conclusions First-line pembro plus trastuzumab and chemo provided a statistically significant and clinically meaningful improvement in OS vs pbo plus trastuzumab and chemo in ...
1. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study 2. Trastuzumab deruxtecan (DS-8201a) in patients ...
HER2-positive, stage I-IIIA invasive, operable breast cancer with at least one PET-evaluable lesion to either group A, where patients received docetaxel (75 mg/m2, intravenous), carboplatin
Professor Sara Hurvitz:HER2CLIMB-02 was a randomized phase 3 clinical trial that evaluated tucatinib when added to T-DM1 in HER2- positive metastatic breast cancer. Patients who'd previously received trastuzumab and a taxane were allowed, and patients who had a history of brain metastases, includi...
Professor Sara Hurvitz:HER2CLIMB-02 was a randomized phase 3 clinical trial that evaluated tucatinib when added to T-DM1 in HER2- positive metastatic breast cancer. Patients who'd previously received trastuzumab and a taxane were allowed, and patients who had a history of brain metastases, includi...
3项研究评估了紫杉类+CEF+双靶治疗组(拉帕替尼+曲妥珠单抗)相比紫杉类+CEF+拉帕替尼或曲妥珠单抗单靶治疗组的有效性,汇总分析结果显示,双靶治疗组优于拉帕替尼单靶治疗组(OR=2.47,95%CI 1.41-4.34,p=0.002,n=224,3项试验;I2=0%)(图3a)。同样,与曲妥珠单抗单靶组相比,双靶治疗组的pCR率更高(OR=1.89...
[2]Giuliani, S. et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Arch. 469, 45–50 (2016). ...
The standard treatment for HER-2 positive women is trastuzumab, a monoclonal antibody that is designed to inhibit the cancer-causing activity of the HER2 protein. Another HER-2 drug to target the disease is pertuzumab, a drug that acts as a complementary therapy to trastuzumab, and which has ...
Meta分析表明,抗HER2双靶新辅助治疗能为HER2阳性乳腺癌患者带来更多生存获益。HER2是乳腺癌重要的驱动基因和预后指标,也是抗HER2药物治疗的主要预测指标。诸如单克隆抗体、酪氨酸激酶抑制剂(TKI)以及抗体药物偶联物(ADC)等抗HER2治疗药物不断研发成功上市,在HER2
Professor Sara Hurvitz:HER2CLIMB-02 was a randomized phase 3 clinical trial that evaluated tucatinib when added to T-DM1 in HER2- positive metastatic breast cancer. Patients who'd previously received trastuzumab and a taxane ...